ClinicalTrials.gg

Program

vilanterol

Also written as “GW642444”, “FF/UMEC/VI” and “Vilanterol”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by 2 companies.

Furthest: phase 4, since Oct 4, 201380 company-led studies, 1 open or runningNext primary completion: Jan 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline791 open or runningphase 4since Oct 4, 2013Jun 29, 2006Jan 26, 2027phase 3 · NCT05757102
Sandoz10 open or runningphase 3since Oct 15, 2025Oct 15, 2025none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since May 6, 2010.

  1. May 14, 2015Phase 3 study in AsthmaGlaxoSmithKline · NCT02446418 · 423 enrolled · France, Germany
  2. Jan 25, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02666287 · 48 enrolled · United Kingdom
  3. Mar 14, 2016Phase 2 study in AsthmaGlaxoSmithKline · NCT02712047 · 28 enrolled · New Zealand
  4. Mar 24, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02730351 · 75 enrolled · United States, Canada
  5. Nov 30, 2017Phase 4 study in AsthmaGlaxoSmithKline · NCT03363191
  6. Dec 1, 2017Phase 3 study in AsthmaGlaxoSmithKline · NCT03376932
  7. Feb 2, 2018Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03467425 · 3,109 enrolled · Germany, Netherlands, Spain and more
  8. Mar 15, 20183 phase 4 studies in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03474081, NCT03478696, NCT03478683
  9. May 13, 2019Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03949842 · United States
  10. Jun 2, 2021Phase 3 study in AsthmaGlaxoSmithKline · NCT04937387 · 359 enrolled · China
  11. Jun 6, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT04923347 · 229 enrolled · India
  12. Sep 7, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT05535972 · 463 enrolled · China
  13. Feb 24, 2023Phase 3 study in AsthmaGlaxoSmithKline · NCT05757102 · 138 enrolled · United States, Argentina, Australia and more
  14. Oct 15, 2025Sandoz's first study: phase 3 study in RespiratoryNew to SandozSandoz · NCT07223294

Ahead

  1. Jan 26, 2027Primary completion: phase 3 study in AsthmaGlaxoSmithKline · NCT05757102

TargetBeta

ADRB2 →read by rule
“Beta-2 adrenergic receptor agonist”ChEMBL 37, by rule

Other programs on ADRB2

ProgramCompanyFurthest phaseStudies
TimololruleAbbViephase 427
Epinephrinerulenasus-pharmaphase 417
TQC3927Sino Biopharmaceuticalphase 23
TQC3302Sino Biopharmaceuticalphase 11

Studies

The newest 60 of 80 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07223294Respiratory3WithdrawnSandozApr 21, 20260
NCT05757102Asthma · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineJan 26, 2027138
NCT05535972Pulmonary Disease, Chronic Obstructive · China4CompletedGlaxoSmithKlineSep 25, 2023463
NCT04923347Pulmonary Disease, Chronic Obstructive · India4CompletedGlaxoSmithKlineMar 14, 2024229
NCT04937387Asthma · China3CompletedGlaxoSmithKlineAug 5, 2024359
NCT03949842Pulmonary Disease, Chronic Obstructive · United States4WithdrawnGlaxoSmithKlineNov 30, 20220
NCT03478696Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany4CompletedGlaxoSmithKlineMar 18, 2019732
NCT03478683Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more4CompletedGlaxoSmithKlineMar 14, 2019729
NCT03474081Pulmonary Disease, Chronic Obstructive · United States, Poland, Russian Federation4CompletedGlaxoSmithKlineJul 17, 2019800
NCT03467425Pulmonary Disease, Chronic Obstructive · Germany, Netherlands, Spain and more4CompletedGlaxoSmithKlineOct 10, 20193,109
NCT03376932Asthma3WithdrawnGlaxoSmithKlineFeb 3, 20210
NCT03363191Asthma4WithdrawnGlaxoSmithKlineMay 29, 20190
NCT02730351Asthma · United States, Canada4CompletedGlaxoSmithKlineFeb 3, 201775
NCT02712047Asthma · New Zealand2CompletedGlaxoSmithKlineFeb 21, 201728
NCT02666287Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedGlaxoSmithKlineJun 3, 201648
NCT02446418Asthma · France, Germany3CompletedGlaxoSmithKlineJul 20, 2017423
NCT02105974Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Germany and more3CompletedGlaxoSmithKlineJul 8, 20151,621
NCT02094937Asthma · Japan3CompletedGlaxoSmithKlineAug 28, 2015430
NCT01957150Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more4CompletedGlaxoSmithKlineMar 26, 2018283
NCT01899742Pulmonary Disease, Chronic Obstructive · United States, Argentina, Estonia and more3CompletedGlaxoSmithKlineJul 22, 2015497
NCT01822899Pulmonary Disease, Chronic Obstructive · Czechia, Denmark, Germany and more3CompletedGlaxoSmithKlineOct 1, 2013717
NCT01817764Pulmonary Disease, Chronic Obstructive · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineOct 1, 2013707
NCT01777334Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedGlaxoSmithKlineSep 24, 2013905
NCT01706198Asthma · United Kingdom3CompletedGlaxoSmithKlineDec 1, 20164,233
NCT01686633Asthma · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineOct 1, 20131,040
NCT01711463Asthma · China1CompletedGlaxoSmithKlineJun 4, 201316
NCT01691885Pulmonary Disease, Chronic Obstructive · United Kingdom3CompletedGlaxoSmithKlineJul 201445
NCT01627327Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedGlaxoSmithKlineDec 1, 2012623
NCT01571999Pulmonary Disease, Chronic Obstructive · Czechia, Hungary1CompletedGlaxoSmithKlineJun 22, 201217
NCT01577680Pulmonary Disease, Chronic Obstructive · Hungary, Slovakia1CompletedGlaxoSmithKlineJun 29, 201218
NCT01573767Asthma · United States, Argentina, Chile and more2CompletedGlaxoSmithKlineApr 2014463
NCT01551758Pulmonary Disease, Chronic Obstructive · United Kingdom3CompletedGlaxoSmithKlineNov 24, 20152,802
NCT01498679Asthma · China, Korea, Republic of, Philippines3CompletedGlaxoSmithKlineJul 2013311
NCT01498653Asthma · China, Korea, Republic of, Philippines3CompletedGlaxoSmithKlineFeb 2013313
NCT01485445Asthma · Germany1CompletedGlaxoSmithKlineMar 12, 201230
NCT01453023Asthma · United States2CompletedGlaxoSmithKlineJun 201226
NCT01435902Asthma3WithdrawnGlaxoSmithKlineAug 20120
NCT01453296Asthma · United States2CompletedGlaxoSmithKlineApr 201128
NCT01395888Pulmonary Disease, Chronic Obstructive · Argentina, France, Germany and more3CompletedGlaxoSmithKlineAug 1, 2012260
NCT01376388Pulmonary Disease, Chronic Obstructive · Japan3CompletedGlaxoSmithKlineDec 2012131
NCT01376245Pulmonary Disease, Chronic Obstructive · China, Korea, Republic of, Philippines and more3CompletedGlaxoSmithKlineSep 2012646
NCT01328444Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Estonia and more3CompletedGlaxoSmithKlineJun 1, 2012349
NCT01336608Pulmonary Disease, Chronic Obstructive · United States, Germany, Korea, Republic of and more3CompletedGlaxoSmithKlineNov 4, 2014446
NCT01323660Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedGlaxoSmithKlineJul 1, 2012307
NCT01316913Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineApr 2012872
NCT01316900Pulmonary Disease, Chronic Obstructive · United States, France, Germany and more3CompletedGlaxoSmithKlineApr 1, 2012846
NCT01313637Pulmonary Disease, Chronic Obstructive · United States, Belgium, Denmark and more3CompletedGlaxoSmithKlineMar 1, 20121,493
NCT01313676Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJul 15, 201516,568
NCT01244984Asthma · Japan3CompletedGlaxoSmithKlineJan 2012243
NCT01213849Asthma · United Kingdom1CompletedGlaxoSmithKlineNov 25, 201024
NCT01209026Asthma · United Kingdom1CompletedGlaxoSmithKlineJan 4, 201185
NCT01192191Pulmonary Disease, Chronic Obstructive · Japan3CompletedGlaxoSmithKlineJan 2012187
NCT01181895Asthma · United States, Germany, Peru and more3CompletedGlaxoSmithKlineAug 1, 2011348
NCT01165138Asthma · United States, Germany, Japan and more3CompletedGlaxoSmithKlineOct 1, 2011612
NCT01165125Asthma · United Kingdom1CompletedGlaxoSmithKlineAug 28, 201018
NCT01299558Asthma · Australia1CompletedGlaxoSmithKlineJul 15, 201016
NCT01147848Asthma · United States, Argentina, Chile and more3CompletedGlaxoSmithKlineJul 2011810
NCT01134042Asthma · United States, Germany, Japan and more3CompletedGlaxoSmithKlineOct 2011587
NCT01128569Asthma · Germany, New Zealand, United Kingdom2CompletedGlaxoSmithKlineOct 201052
NCT01286831Pulmonary Disease, Chronic Obstructive · Netherlands1CompletedGlaxoSmithKlineJul 9, 20106

How it is read

Names in the registry

  • “GW642444”, 15 entries
  • “FF/UMEC/VI”, 9 entries
  • “Vilanterol”, 8 entries
  • “Fluticasone Furoate/Vilanterol”, 7 entries
  • “FF/GW642444 Inhalation Powder”, 4 entries

Codes read as this program: GW642444.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.